Clinical Trials
6
Active:3
Completed:1
Trial Phases
2 Phases
Phase 1:4
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 3
1 (20.0%)Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism
Phase 3
Active, not recruiting
- Conditions
- Endocrine System DiseasesParathyroid DiseasesChronic Hypoparathyroidism
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Amolyt Pharma
- Target Recruit Count
- 165
- Registration Number
- NCT05778071
- Locations
- 🇯🇵
Osaka City Hospital, Osaka, Japan
🇯🇵Tokushima University Hospital, Tokushima, Japan
🇺🇸Harbor UCLA Medical Center Endocrinology, Torrance, California, United States
AZP-3601 SAD and MAD Study in Healthy Subjects and Patients With Hypoparathyroidism
- First Posted Date
- 2022-02-14
- Last Posted Date
- 2024-01-31
- Lead Sponsor
- Amolyt Pharma
- Target Recruit Count
- 132
- Registration Number
- NCT05239221
- Locations
- 🇭🇺
Amolyt Pharma Investigational Site Hungary, Budapest, Hungary
🇳🇱PRA-EDS, Groningen, Netherlands
News
Sofinnova Partners Secures €1.2 Billion to Fuel Next Wave of Biotech Innovation
European venture capital firm Sofinnova Partners has raised €1.2 billion ($1.3 billion) in fresh funds to invest in life sciences and healthcare companies, with plans to support 50-60 new ventures.